` HLN (HALEON PLC) vs FTSE All Share Index Comparison - Alpha Spread

HLN
vs
FTSE All Share Index

Over the past 12 months, HLN has significantly outperformed FTSE All Share Index, delivering a return of 24% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
HLN vs FTSE All Share Index

Loading
HLN
FTSE All Share Index
Add Stock
www.alphaspread.com

Performance Gap
HLN vs FTSE All Share Index

Loading
HLN
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
HLN vs FTSE All Share Index

Loading
HLN
FTSE All Share Index
Add Stock

Competitors Performance
HALEON PLC vs Peers

FTSE All Share Index
HLN
OR
ULVR
HINDUNILVR
BEI
Add Stock

HALEON PLC
Glance View

Market Cap
36.1B GBX
Industry
Consumer products

In the bustling world of consumer healthcare, HALEON PLC stands as a luminary figure, emerging with a focused mission: to deliver everyday health with humanity. Spun off from the pharmaceutical giant GlaxoSmithKline, HALEON now charts its independent course, concentrating on the development and distribution of over-the-counter medications, oral health products, and nutritional supplements. Its diverse portfolio includes household names such as Sensodyne, Panadol, and Centrum, demonstrating its wide-reaching impact on consumers’ health routines. These brands are not merely market fixtures; they represent HALEON’s commitment to blending scientific innovation with consumer insights, aiming to enhance well-being across the globe. HALEON’s business model is poised at the intersection of healthcare and retail, thriving through an intricate blend of strategic marketing, global distribution networks, and strong brand equity. By leveraging extensive consumer research data, HALEON aligns its product offerings with the evolving needs and preferences of its audience. The company generates revenue primarily through product sales, employing an omnichannel strategy that ensures product availability across various retail and digital platforms. Its strategic alliances and network with pharmacies, supermarkets, and online marketplaces cement its accessibility and prominence in the market. Additionally, HALEON's stream of revenue is bolstered by its investment in innovation—a key driver that keeps its product lines relevant and competitive in a dynamic healthcare landscape.

HLN Intrinsic Value
347.86 GBX
Overvaluation 13%
Intrinsic Value
Price
Back to Top